Relevance of serologic studies in inflammatory bowel disease

Current Gastroenterology Reports

Volumn 6, Issue 6, 2004, Pages 482-487

  Vernier, Gwenola ^b   Sendid, Boualem ^b   Poulain, Daniel ^b   Colombel, Jean Frédéric ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; FLAGELLIN; INFLIXIMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; CROSS REACTION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DRUG RESPONSE; ENTERITIS; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; INTESTINE SURGERY; LABORATORY DIAGNOSIS; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; REVIEW; SACCHAROMYCES CEREVISIAE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SEROPREVALENCE; TREATMENT FAILURE; ULCERATIVE COLITIS;

EID: 9944231919     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-004-0070-x     Document Type: Review

References (36)

1. Reumaux D, Sendid B, Poulain D, et al.: Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 2003, 17:19-35.
2. Colombel JF, Reumaux D, Sendid B, et al.: Serodiagnostics in IBD. In The Inflammatory Bowel Disease Yearbook 2003. Edited by Bernstein CN. London: Remedica; 2003:63-78.
3. Klebl FH, Bataille F, Hofstadter F, et al.: Optimising the diagnostic value of Anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Int J Colorectal Dis 2004, 19:319-324.
4. Sendid B, Colombel JF, Jacquinot PM, et al.: Specific antibody response to oligomannosidic epitopes in Crohn's disease Clin Diagn Lab Immunol 1996, 3:219-226.
5. Vandewalle P, Standaert A, Seddik M, et al.: A new ASCA test based on synthetic oligomannosides epitopes complements ASCA detection in both Crohn's disease and indeterminate colitis [abstract] Gastroenterology 2004, 126:A112.
6. Joossens S, Vermeire S, Van Steen C, et al.: Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis 2004, in press.
7. Landers CJ, Cohavy O, Misra R, et al.: Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002, 123: 89-699.
8. Linskens RK, Mallant-Hent RC, Groothuismink ZMA, et al. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol 2002, 14:1013-1017.
9. Lodes MJ, Cong Y, Elson CO, et al.: Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004, 113:1296-1306.
10. Targan S, CJ L, Lodes M, et al.: Antibodies to a novel flagellin (CBir1) define a unique serologic response in Crohn's disease [abstract]. Gastroenterology 2004, 126:A112.
11. Damoiseaux JG, Bouten B, Linders AM, et al.: Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. J Clin Immunol 2002, 22: 81-288.
12. Escher JC: Serologic tests are helpful in managing but not in diagnosing IBD. Inflamm Bowel Dis 2002, 8:230-321.
13. Dubinsky MC, Ofman JJ, Urman M, et al.: Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001, 96:758-765.
14. Dubinsky MC, Johanson JF, Seidman EG, Ofman JJ. Suspected inflammatory bowel disease: the clinical and economic impact of competing diagnostic strategies. Am J Gastroenterol 2002, 97: 333-2342.
15. Khan K, Schwarzenberg SJ, Sharp H, et al.: Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm Bowel Dis 2002, 8:325-329.
16. Gupta SK, Fitzgerald JF, Croffie JM, et al.: Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children. Inflamm Bowel Dis 2004, 10: 40-244.
17. Panaccione R, Sandborn WJ: Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology 1999, 116:1001-1002.
18. Joossens S, Reinisch W, Vermeire S, et al.: The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002, 122:1242-1247.
19. Plevy S: Do serological markers and cytokines determine the indeterminate? J Clin Gastroenterol 2004, 38:S51-S56.
20. Aisenberg J, Legnani PE, Nilubol N, et al.: Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol 2004, 99:432-441.
21. Klebl FH, Bataille F, Bertea CR, et al.: Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis 2003, 9: 02-307.
22. Walker LJ, Aldhous MC, Drummond HE, et al.: Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004, 135:490-496.
23. Mow WS, Vasiliauskas EA, Lin YC, et al.: Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004, 126:414-424.
24. Teml A, Kratzer V, Schneider B, et al.: Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003, 98:2226-2231.
25. Canani RB, Romano MT, Greco L, et al.: Effects of disease activity on anti-Saccharomyces cerevisiae antibodies: implications for diagnosis and follow-up of children with Crohn's disease Inflamm Bowel Dis 2004, 10:234-239.
26. Desir B, Amre DK, Lu SE, et al.: Utility of serum antibodies in determining clinical course in pediatric Crohn's disease Clin Gastroenterol Hepatol 2004, 2:139-146.
27. Taylor KD, Plevy SE, Yang H, et al.: ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001, 120: 347-1355.
28. Esters N, Vermeire S, Joossens S, et al.: Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002, 97:1458-1462.
29. Fleshner PR, Vasiliauskas E, Kam LY, et al.: High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001, 49: 71-677.
30. Spivak J, Targan S, Vasiliauskas E, et al.: Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease [abstract]. Gastroenterology 2004, 126:A69.
31. Scofield RH. Autoantibodies as predictors of disease. Lancet 2004, 363:1544-1546.
32. Nielen MM, van Schaardenburg D, Reesink HW, et al.: Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386.
33. Arbuckle MR, McClain MT, Rubertone MV, et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
34. Oshitani N, Hato F, Suzuki K, et al.: Cross-reactivity of yeast antigens in human colon and peripheral leukocytes. J Pathol 2003, 199:361-367.
35. Vermeire S, Peeters M, Vlietinck R, et al.: Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001, 7:8-15.
36. Harrer M, Reinisch W, Dejaco C, et al.: Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur J Gastroenterol Hepatol 2003, 15:1281-1285.